Promising combo targets Hard-to-Treat breast cancer brain metastases
NCT ID NCT06238921
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 35 times
Summary
This study tests whether adding two drugs (sacituzumab govitecan and zimberelimab) to targeted brain radiation can help people with a tough-to-treat type of breast cancer that has spread to the brain. About 31 adults with triple negative breast cancer and brain metastases will take part. The goal is to see if the combination is safe and helps keep the cancer from growing longer than the standard drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.